Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (DE:AT2)
FRANKFURT:AT2
Atara Biotherapeutics (AT2) Stock Price & Analysis
0 Followers
AT2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.18 - €2.11
Previous Close€0.62
Volume0.00
Average Volume (3M)3.17K
Market Cap
€72.11M
Enterprise Value€22.47M
Total Cash (Recent Filing)$102.41M
Total Debt (Recent Filing)$48.51M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Aug 05, 2024EPS Estimate
-€0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding120,416,138
10 Day Avg. Volume0
30 Day Avg. Volume3,174
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-0.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.26
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
€3.85Price Target Upside521.10% Upside
Rating ConsensusHold
Number of Analyst Covering6
Atara Biotherapeutics News
PremiumCompany Announcements
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
Bulls Say, Bears Say
Bulls Say
Clinical Research AdvancementsATA3219's IND clearance for lupus nephritis and upcoming Phase 1 trial signify Atara's progress in expanding its portfolio into autoimmune disease treatments.
Financial PerformanceAtara's narrower than expected net loss per share indicates improved financial management and potential for enhanced investor confidence.
Regulatory MilestonesTab-cel BLA submitted to the FDA for the treatment of EBV+ PTLD could lead to milestone payments from Pierre Fabre, boosting financial incentives upon successful acceptance and approval.
Bears Say
Financial PerformanceATRA's reported total revenue falls short of Goldman Sachs' estimates, signaling potential concerns over the company's financial health.
Regulatory ApprovalRejection of the tab-cel BLA by the FDA could adversely affect the stock's performance.
Stock DilutionThe possibility of medium to long-term dilution risk may erode shareholder value over time.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
28.01% Other Institutional Investors
71.99% Public Companies and
Individual Investors
AT2 FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was €0.18 and its highest was €2.11 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Currently, no data Available
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 72 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on May 08, 2024. The company reported -€0.212 earnings per share for the quarter, beating the consensus estimate of -€0.237 by €0.025.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -€0.08.
How many shares outstanding does Atara Biotherapeutics have?
Currently, no data Available
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -€0.212 in its last earnings report, beating expectations of -€0.237. Following the earnings report the stock price went down -10.714%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at 1M.
---
Atara Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.85 (521.10% Upside)
€3.85 (521.10% Upside)
Blogger Sentiment
Neutral
DE:AT2 Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $169.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.29%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
AT2 Earnings Call
Q3 2023
0:00 / 0:00
---
AT2 Stock 12 Month Forecast
Average Price Target
€3.85
▲(521.10% Upside)
Technical Analysis
Atara Biotherapeutics
―
Advaxis
―
Sorrento Therapeutics
―
Kura Oncology
―
Gilead Sciences
―
Best Analysts Covering AT2
1 Year
1 Year Success Rate
20/40 ratings generated profit
1 Year Average Return
+16.89%
reiterated a buy rating 17 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.89% per trade.
---